Indications:

• Schizophrenia
• Moderate to severe manic episodes associated with bipolar disorders
• Short-term treatment (up to 6 weeks) of persistent aggression in patients with moderate to severe Alzheimer’s dementia unresponsive to non-pharmacological approaches and when there is a risk of harm to self or others
• Short-term symptomatic treatment (up to 6 weeks) of persistent aggression in conduct disorder in children from the age of 5 years and adolescents with subaverage intellectual functioning or mental retardation diagnosed according to DSM-IV criteria, in whom the severity of aggressive or other disruptive behaviours require pharmacologic treatment. Pharmacological treatment should be an integral part of a more comprehensive treatment programme, including psychosocial and educational intervention. It is recommended that risperidone be prescribed by a specialist in child neurology and child and adolescent psychiatry or physicians well familiar with the treatment of conduct disorder of children and adolescents.

Administration and dosage: According to a doctor prescription.

Contraindications:

Hypersensitivity to the active substance or to any of the excipients
Galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption.

Packing:

Risperidone-Remedica 2mg – 10 light peach, f/c tablets with break line on one side in a blister. 10 blisters (60 f/c tablets) in a cardboard box along with a leaflet.

Produced by: “Remedica”, Cyprus.

See also:   http://www.remedica.eu